Veozah Vms denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for veozah vms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC May Apply Quantity Limits to Veozah

Veozah (fezolinetant) treats moderate-to-severe vasomotor symptoms (VMS) associated with menopause. UnitedHealthcare's quantity-limit policy restricts how many tablets or how many days' supply may be dispensed per authorization period — typically aligned with the FDA-approved dosing regimen described in the prescribing label. A quantity-limit denial arises when the prescription as written exceeds those preset limits, even when the prescribing physician has determined the requested quantity is medically appropriate.

## Why This Is Appealable

Quantity limits are set to match standard labeled dosing and are not intended to restrict access to patients who require a supply consistent with the label. If the prescription as written matches the FDA-approved regimen, the denial may reflect a data-entry or system error. If you are requesting a supply that exceeds the standard limit for a clinical reason, the denial is appealable by demonstrating medical necessity for the requested quantity — for example, a longer supply needed for continuity during travel, or a clinical judgment supporting a specific dispensing schedule. Obtain the exact dose and approved regimen from the FDA-approved prescribing label and confirm that your prescription aligns with it.

## Federal Appeal Framework

• Internal appeal (ACA/ERISA §503): File within the timeframe stated on the denial notice. Request the specific quantity-limit policy UHC applied and the number of tablets/days they will cover versus what was requested.
• Expedited review: Available if delay in obtaining the medication would significantly impair function or cause clinical harm.
• External review (ACA §2719): If the internal appeal fails, request independent external review within approximately four months of the final denial. External reviewers assess whether the quantity limit, as applied to your specific clinical situation, was justified.

## Documentation to Gather

1. Prescription as written: Confirm the submitted prescription matches the FDA-approved dosing regimen in the Veozah prescribing label. A mismatch between the prescription and the label is the most common and easiest-to-fix source of a QL denial. 2. Diagnosis and severity: Office notes confirming moderate-to-severe VMS diagnosis and the ongoing clinical need for treatment. 3. Continuity justification (if excess supply): If requesting more than the standard supply, the prescriber should document the specific clinical or logistical reason (e.g., extended travel, difficulty accessing pharmacy, clinical judgment on refill schedule). 4. Prescriber medical-necessity letter: Confirming the quantity requested is consistent with the FDA label and the patient's ongoing clinical need; addressing the specific quantity-limit threshold in UHC's policy. 5. UHC's quantity-limit policy: Obtain the current policy from your plan documents or UHC's provider portal to confirm the exact limit and any exception criteria.

## Criteria-Mapping Structure for Your Appeal Letter

| UHC Quantity-Limit Criterion | Your Documentation | |---|---| | Prescribed quantity consistent with FDA-labeled regimen | Compare prescription to prescribing label; confirm match | | Clinical need for continued treatment | Ongoing VMS severity from recent office notes | | Justification for requested supply period | Prescriber explanation if supply exceeds standard limit | | No clinical reason to restrict below labeled quantity | Prescriber letter confirming labeled-regimen use |

For most quantity-limit denials, verifying that the prescription precisely matches the FDA-approved label — and documenting that alignment in the appeal — resolves the denial at the internal review level.